Lipitor

Phase 2Small molecule

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lipitor is one of 98 small molecule programs targeting Toxicity. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxicityRecruiting

Kidney TransplantActive, not recruiting

Magnetic Resonance ImagingTerminated

Dialysis PatientsCompleted

ToxicityPhase 2

Recruiting

Kidney TransplantPreclinical

Active, not recruiting

Magnetic Resonance ImagingPreclinical

Terminated

Dialysis PatientsPreclinical

Completed

Competition

Competitive Landscape

114 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Ultomiris

AstraZeneca

Phase 3

1 2

Kerendia

Bayer

Phase 2

1 3

Felzartamab

Biogen

Phase 3

1 4

Biological/vaccine

Vertex Pharmaceuticals

Phase 3

1 5

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 6

Zemplar

AbbVie

Preclinical

2 7

Cysteine Hydrochloride

Novartis

Preclinical

1 8

Sensipar

Amgen

Preclinical

1 9

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 10

Radicava

Shionogi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Toxicity

NCT05559164

Clinical

Trials by Indication[1]

Atorvastatin2 trials

Bioavailability Study for New Atorvastatin Formulation

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00844376·12 enrolled

Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-lowering Strategy

Completed·QQueen's University··NCT00299884·45 enrolled

Hypercholesterolemia1 trial

Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia

Completed·OOrient Pharma Co., Ltd.·Phase 3·NCT01710007·202 enrolled

Pediatric1 trial

Bioequivalence Study On Pediatric Appropriate Formulation

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 1·NCT00777517·76 enrolled

Polycystic Ovary Syndrome1 trial

A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol

Completed·MMilton S. Hershey Medical Center·Phase 2·NCT00529542·20 enrolled

Mitochondria1 trial

Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity

Completed·UUniversity of Kansas Medical Center·Phase 4·NCT03351998·68 enrolled

5 more indications

Exercise1 trial

Impact of Statin Therapy on Adaptations to Aerobic Exercise

Completed·UUniversity of Kansas Medical Center·Phase 4·NCT03360916·52 enrolled

Toxicity1 trial

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT05559164·60 enrolled

Kidney Transplant1 trial

Pediatric Kidney Transplant Without Calcineurin Inhibitors

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00023231·35 enrolled

Dialysis Patients1 trial

Effect of Statins on IgG, IgA and IgM Level in Chronic Hemodialysis Patients

Completed·HHormozgan University of Medical Sciences·N/A·NCT01305317·74 enrolled

Magnetic Resonance Imaging1 trial

Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging

Terminated·JJohns Hopkins University·N/A·NCT00770679·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Lipitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lipitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lipitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lipitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Atorvastatin2 trials

Hypercholesterolemia1 trial

Pediatric1 trial

Polycystic Ovary Syndrome1 trial

Mitochondria1 trial

Exercise1 trial

Toxicity1 trial

Kidney Transplant1 trial

Dialysis Patients1 trial

Magnetic Resonance Imaging1 trial

References

Drug Info

Quick Facts

Related News